drug,ticker,stage,end_date,date_text,price
Trulance (plecanatide),SGYP,PDUFA,01/24/2018,,2.40
Plinabulin (Trial 105),BYSI,Phase 2/3,01/25/2018,,25.97
Lutathera,AAAP,PDUFA,01/26/2018,,81.99
Linhaliq (Pulmaquin),ARDM,PDUFA priority review,01/26/2018,,2.29
KD025,KDMN,Phase 2,01/31/2018,January 2018;,4.88
Feraheme,AMAG,PDUFA,02/02/2018,,13.85
Tivozanib + Opdivo,AVEO,Phase 1/2,02/08/2018,"February 8-10, 2018;",2.93
DE-122 and Lucentis - AVANTE,TCON,Phase 2,02/10/2018,,2.80
Bictegravir/F/TAF,GILD,PDUFA priority review,02/12/2018,,80.98
Plenvu (NER1006),VRX,PDUFA,02/13/2018,,21.52
Makena - auto injector,AMAG,PDUFA,02/14/2018,,13.85
Makena - auto injector,ATRS,PDUFA,02/14/2018,,2.25
EXPAREL,PCRX,PDUFA,02/14/2018,Adcom 2/14/18; PDUFA 4/6/18;,38.75
Tipifarnib,KURA,Phase 2,02/15/2018,"February 15-17, 2018;",17.80
Vitaros,APRI,PDUFA,02/17/2018,,2.65
Bertilimumab,IMNP,Phase 2,02/17/2018,,0.59
KP201/APAP,KMPH,PDUFA,02/23/2018,,5.66
AR101 PALISADE,AIMT,Phase 3,02/28/2018,February 2018;,38.90
AST-OPC1 SCiSTAR,AST,Phase 1/2,02/28/2018,February 2018;,2.40
Neutrolin - LOCK-IT 100,CRMD,Phase 3,02/28/2018,Early 2018;,0.49
MGL-3196,MDGL,Phase 2,02/28/2018,Early 2018;,124.59
Ganaxolone,MRNS,Phase 2,02/28/2018,Early 2018;,6.83
NanoFlu vaccine,NVAX,Phase 1/2,02/28/2018,Feb 2018;,1.97
RXI-109-1501,RXII,Phase 1/2,02/28/2018,Early 2018;,4.42
ZTlido (lidocaine patch 1.8%),SRNE,PDUFA,02/28/2018,,6.40
SRA737,SRRA,Phase 1,02/28/2018,February 2018;,3.19
Tezacaftor (VX-661) / ivacaftor,VRTX,PDUFA priority review,02/28/2018,,157.97
OTIPRIO,OTIC,PDUFA,03/02/2018,,5.68
Opdivo -  4 week applications,BMY,PDUFA,03/05/2018,,62.28
Xeljanz,PFE,PDUFA,03/08/2018,,36.94
Natalizumab (α4-integrin inhibitor),BIIB,Phase 2b,03/30/2018,Early-2018;,342.41
Gencaro - GENETIC-AF trial,ABIO,Phase 2b,03/31/2018,March 2018;,1.60
Tozadenant,ACOR,Phase 3,03/31/2018,1Q 2018;,27.20
NasoVAX,ALT,Phase 1/2,03/31/2018,1Q 2018;,1.82
ANB020,ANAB,Phase 2a,03/31/2018,1Q 2018;,114.91
Sollpura - RESULT,ANTH,Phase 3,03/31/2018,1Q 2018;,1.28
APD371,ARNA,Phase 2,03/31/2018,1Q or 2Q 2018;,35.60
Etrasimod,ARNA,Phase 2,03/31/2018,1Q 2018;,35.60
Rimegepant,BHVN,Phase 3,03/31/2018,1Q 2018;,31.24
Prexigebersen,BPTH,Phase 2,03/31/2018,Early 2018;,0.22
CB 2679d/ ISU304,CBIO,Phase 1/2,03/31/2018,Early 2018;,19.49
Rezafungin (CD101) IV - STRIVE,CDTX,Phase 2,03/31/2018,1Q 2018;,7.30
REVLIMID - AUGMENT NHL-007,CELG,Phase 3,03/31/2018,1Q 2018;,102.65
OTEZLA,CELG,Phase 2,03/31/2018,1Q 2018;,102.65
Suprachoroidal CLS-TA - PEACHTREE,CLSD,Phase 3,03/31/2018,1Q 2018;,6.44
CORT125134,CORT,Phase 2,03/31/2018,1Q 2018;,23.98
CK-2127107,CYTK,Phase 2,03/31/2018,1Q 2018;,9.60
Olumacostat glasaretil (DRM01),DERM,Phase 3,03/31/2018,1Q 2018;,28.21
Keyzilen (AM-101) - TACTT3,EARS,Phase 3,03/31/2018,1Q 2018 - likely February;,0.50
EG-1962,EDGE,Phase 3,03/31/2018,1Q 2018;,12.40
Bempedoic Acid - 1002-039,ESPR,Phase 2,03/31/2018,1Q 2018;,77.20
"Bempedoic acid - CLEAR LDL-C Lowering Program 1002-046, 1002-047 and 1002-048",ESPR,Phase 3,03/31/2018,"March, May and September 2018;",77.20
EGP-437,EYEG,Phase 2b,03/31/2018,1Q 2018.;,1.19
FLX-787 (Aust),FLKS,Phase 2,03/31/2018,1Q 2018;,3.85
NeuVax in combination with Herceptin,GALE,Phase 2b,03/31/2018,1Q 2018;,0.26
Imetelstat - IMbarkStudy,GERN,Phase 2,03/31/2018,1Q 2018;,1.92
GS-9674,GILD,Phase 2,03/31/2018,1Q 2018;,80.98
GS-5745,GILD,Phase 3,03/31/2018,1Q 2018;,80.98
GS-9674,GILD,Phase 2,03/31/2018,1Q 2018;,80.98
Entospletinib,GILD,Phase 2,03/31/2018,1Q 2018;,80.98
Aramchol - ARRIVE,GLMD,Phase 2,03/31/2018,1Q 2018;,10.57
Dolutegravir + lamivudine (GEMINI 2),GSK,Phase 3,03/31/2018,1Q 2018;,38.20
Dolutegravir + lamivudine (GEMINI 1),GSK,Phase 3,03/31/2018,1Q 2018;,38.20
Trilaciclib,GTHX,Phase 2,03/31/2018,1Q 2018;,26.34
Epidiolex,GWPH,Phase 3,03/31/2018,1Q 2018;,132.42
GWP42006 (CBDV),GWPH,Phase 2,03/31/2018,1Q 2018;,132.42
Mirvetuximab soravtansine - FORWARD II,IMGN,Phase 1/2,03/31/2018,1Q 2018;,8.03
Mirvetuximab soravtansine - FORWARD I,IMGN,Phase 3,03/31/2018,1Q 2018;,8.03
IMM-124E,IMRN,Phase 2,03/31/2018,1Q 2018;,7.11
MB-102,MBIO,Phase 1,03/31/2018,Early 2018;,12.25
MB-101,MBIO,Phase 1,03/31/2018,Early 2018;,12.25
MVT-1075,MBVX,Phase 1,03/31/2018,1Q 2018;,0.88
MVT-5873,MBVX,Phase 1/2,03/31/2018,1Q 2018;,0.88
SER-262,MCRB,Phase 1b,03/31/2018,Early 2018;,10.57
MPC-150-IM - Class IV,MESO,Phase 2b,03/31/2018,1Q 2018;,5.89
MSC-100-IV,MESO,Phase 3,03/31/2018,1Q 2018;,5.89
Mocetinostat and durvalumab,MRTX,Phase 2,03/31/2018,1Q 2018 - see note below;,25.60
MYK-461 - PIONEER-HCM,MYOK,Phase 2,03/31/2018,1Q 2018;,53.95
Elagolix,NBIX,Phase 3,03/31/2018,1Q 2018;,80.68
Semaglutide - oral - PIONEER,NVO,Phase 3,03/31/2018,1Q 2018;,57.79
OBE001 - IMPLANT2,OBSV,Phase 2,03/31/2018,1Q 2018;,9.73
OPRX-106,PLX,Phase 2,03/31/2018,1Q 2018;,0.71
PTG-100,PTGX,Phase 2b,03/31/2018,Early 2018;,18.99
PTI-428 + Kalydeco,PTI,Phase 1,03/31/2018,1Q 2018;,4.16
Cemiplimab,REGN,Phase 2,03/31/2018,1Q 2018;,371.53
Praluent (alirocumab) ODYSSEY OUTCOMES,REGN,Phase 3,03/31/2018,1Q 2018;,371.53
Bardoxolone methyl - LARIAT,RETA,Phase 2,03/31/2018,1Q 2018;,29.79
Omaveloxolone - MOTOR,RETA,Phase 2,03/31/2018,1Q 2018;,29.79
RG-012,RGLS,Phase 1/2,03/31/2018,1Q 2018;,1.40
RX-3117,RNN,Phase 2a,03/31/2018,1Q 2018;,2.40
Archexin,RNN,Phase 2a,03/31/2018,1Q 2018;,2.40
Ezutromid,SMMT,Phase 2,03/31/2018,1Q 2018;,12.17
Topsalysin (PRX302),SPHS,Phase 2,03/31/2018,Late-1Q 2018;,2.22
SPI-2012 (ROLONTIS),SPPI,Phase 3,03/31/2018,1Q 2018;,19.03
Eravacycline (TP-434) - IGNITE3,TTPH,Phase 3,03/31/2018,1Q 2018;,6.34
VB-111,VBLT,Phase 3,03/31/2018,1Q 2018;,7.75
ASP0113 Vaccine,VICL,Phase 3,03/31/2018,1Q 2018;,1.87
HETLIOZ (tasimelteon),VNDA,Phase 2,03/31/2018,1Q 2018;,14.50
TTP399,VTVT,Phase 1/2,03/31/2018,Early 2018;,5.70
Azeliragon - STEADFAST,VTVT,Phase 3,03/31/2018,Early 2018;,5.70
VY-AADC01,VYGR,Phase 1b,03/31/2018,1Q 2018;,18.67
Keytruda,MRK,PDUFA priority review,04/03/2018,,61.28
Ibalizumab,THERF,PDUFA,04/03/2018,,6.55
Rucaparib ARIEL3,CLVS,PDUFA priority review,04/06/2018,,56.76
Pegylated Interferon Lambda (LIMT HDV),EIGR,Phase 2,04/11/2018,EASL 2018.;,8.85
Abemaciclib - MONARCH 3,LLY,PDUFA priority review,04/12/2018,,85.49
CM-214 – Opdivo + Yervoy,BMY,PDUFA priority review,04/16/2018,,62.28
KRN23 Burosumab,RARE,PDUFA priority review,04/17/2018,,49.16
Fostamatinib,RIGL,PDUFA,04/17/2018,,4.23
Elagolix,NBIX,PDUFA priority review,04/27/2018,,80.68
Lubiprostone,SCMP,PDUFA,04/28/2018,,17.95
ALKS 3831 - ENLIGHTEN-2,ALKS,Phase 3,04/30/2018,Fall 2018;,57.03
KYPROLIS (ENDEAVOR),AMGN,PDUFA,04/30/2018,,189.28
Selinexor - STORM,KPTI,Phase 2b,04/30/2018,April 2018;,10.01
Lefamulin - LEAP 2,NBRV,Phase 3,04/30/2018,Spring 2018;,6.59
Kymriah (CTL019 )- JULIET,NVS,PDUFA priority review,04/30/2018,,86.94
Azedra,PGNX,PDUFA priority review,04/30/2018,,6.27
ADCETRIS  in combination with chemotherapy ECHELON-1,SGEN,PDUFA priority review,05/01/2018,,53.48
Andexanet alfa,PTLA,PDUFA,05/04/2018,,49.63
LPCN 1021,LPCN,PDUFA,05/08/2018,,1.36
Tagrisso - FLAURA,AZN,PDUFA priority review,05/15/2018,Estimate mid-2Q 2018;,35.44
Erenumab,AMGN,PDUFA,05/17/2018,,189.28
Erenumab,NVS,PDUFA,05/17/2018,,86.94
Avatrombopag,DOVA,PDUFA priority review,05/21/2018,,30.90
DARZALEX (Daratumumab) - ALCYONE,JNJ,PDUFA priority review,05/21/2018,,147.36
Pegvaliase,BMRN,PDUFA priority review,05/25/2018,,89.12
Intravenous (IV) meloxicam,REPH,PDUFA,05/26/2018,,8.93
Prolia (denosumab),AMGN,PDUFA,05/28/2018,,189.28
Yuvvexy - TX-004HR,TXMD,PDUFA,05/29/2018,,6.30
Bempedoic acid (ETC-1002-040) - Clear Harmony,ESPR,Phase 3,05/31/2018,May 2018;,77.20
KIT-302,KTOV,PDUFA,05/31/2018,,2.34
Tafinlar (dabrafenib) and Mekinist (trametinib),NVS,PDUFA priority review,05/31/2018,Estimate mid-2Q 2018;,86.94
IMO-2125 + ipilimumab - ILLUMINATE 204,IDRA,Phase 2,06/01/2018,ASCO 2018;,2.55
IDP-118,VRX,PDUFA,06/18/2018,,21.52
Furoscix,SCPH,PDUFA,06/23/2018,,12.19
Plazomicin,AKAO,PDUFA priority review,06/25/2018,,11.54
Epidiolex,GWPH,PDUFA priority review,06/27/2018,,132.42
Rova-T (TRINITY),ABBV,Phase 2,06/30/2018,2Q 2018;,104.64
ATI-50002 - PK/safety,ACRS,Phase 2,06/30/2018,1H 2018;,24.40
ATI-50002 - open label,ACRS,Phase 2,06/30/2018,1H 2018;,24.40
Brimo DDS,AGN,Phase 2,06/30/2018,1H 2018;,181.33
ATOGEPANT,AGN,Phase 2b,06/30/2018,1H 2018;,181.33
UBROGEPANT,AGN,Phase 3,06/30/2018,1H 2018;,181.33
ESMYA  (ulipristal acetate),AGN,PDUFA,06/30/2018,1H 2018;,181.33
ALRN-6924,ALRN,Phase 2a,06/30/2018,1H 2018;,9.21
ANB020,ANAB,Phase 2a,06/30/2018,2Q 2018;,114.91
Cingal,ANIK,Phase 3,06/30/2018,1H 2018;,59.03
APL-2 IV - FILLY,APLS,Phase 3,06/30/2018,1H 2018;,18.90
rocapuldencel-T (AGS-003) ADAPT Trial,ARGS,Phase 3,06/30/2018,1H 2018;,2.17
AGS-004 and vorinostat,ARGS,Phase 1,06/30/2018,1H 2018;,2.17
Binimetinib - COLUMBUS,ARRY,PDUFA,06/30/2018,,13.14
ASN100,ASNS,Phase 2,06/30/2018,1H 2018;,13.63
TIVO-3 - tivozanib,AVEO,Phase 3,06/30/2018,2Q 2018;,2.93
BTA074 5% topical gel,AVIR,Phase 2,06/30/2018,2Q 2018;,0.67
Nelotanserin,AXON,Phase 2,06/30/2018,2Q 2018;,2.03
AXS-05 STRIDE-1,AXSM,Phase 3,06/30/2018,1H 2018;,2.95
Selumetinib - ASTRA,AZN,Phase 3,06/30/2018,1H 2018;,35.44
PT010,AZN,Phase 3,06/30/2018,1H 2018;,35.44
Lynparza,AZN,Phase 3,06/30/2018,1H 2018;,35.44
Durvalumab +/- tremelimumab (MYSTIC),AZN,Phase 3,06/30/2018,1H 2018;,35.44
Durvalumab +/- tremelimumab (KESTREL),AZN,Phase 3,06/30/2018,1H 2018;,35.44
Durvalumab +/- tremelimumab (EAGLE),AZN,Phase 3,06/30/2018,1H 2018;,35.44
Durvalumab +/- tremelimumab (ARCTIC),AZN,Phase 3,06/30/2018,1H 2018;,35.44
CM-714 Opdivo + Yervoy,BMY,Phase 3,06/30/2018,1H 2018;,62.28
CM-511 – Opdivo + Yervoy,BMY,Phase 3,06/30/2018,1H 2018;,62.28
CM-331– Opdivo,BMY,Phase 3,06/30/2018,1H 2018;,62.28
CM-227 – Opdivo + Yervoy,BMY,Phase 3,06/30/2018,1H 2018;,62.28
CM-548 - Opdivo+SOC,BMY,Phase 2,06/30/2018,1H 2018;,62.28
AT342 - VALENS,BOLD,Phase 1/2,06/30/2018,2Q 2018;,37.86
Marzeptacog alfa,CBIO,Phase 2,06/30/2018,1H 2018;,19.49
CK-101,CKPT,Phase 1/2,06/30/2018,1H 2018;,4.65
Glembatumumab vedotin,CLDX,Phase 2b,06/30/2018,2Q 2018;,2.76
Suprachoroidal CLS-TA - TYBEE,CLSD,Phase 2,06/30/2018,2Q 2018;,6.44
Suprachoroidal CLS-TA - HULK,CLSD,Phase 1/2,06/30/2018,2Q 2018;,6.44
Emricasan,CNAT,Phase 2b,06/30/2018,1H 2018;,4.71
Corplex Donepezil,CORI,Phase 1,06/30/2018,1H 2018;,13.63
Firdapse,CPRX,Phase 3,06/30/2018,1H 2018;,3.75
PIXUVRI - PIX306 Trial,CTIC,Phase 3,06/30/2018,1H 2018;,3.50
Viaskin Milk,DBVT,Phase 2b,06/30/2018,1H 2018;,25.05
Glycopyrronium tosylate (DRM04),DERM,PDUFA,06/30/2018,,28.21
DNL201,DNLI,Phase 1,06/30/2018,1H 2018;,19.76
IMblaze370 - cobimetinib and atezolizumab,EXEL,Phase 3,06/30/2018,1H 2018;,28.00
EGP-437,EYEG,Phase 3,06/30/2018,2Q 2018;,1.19
CEVA101,FBIO,Phase 2,06/30/2018,1H 2018;,3.96
Pepvax vaccine,FBIO,Phase 2,06/30/2018,1H 2018;,3.96
IV Tramadol,FBIO,Phase 3,06/30/2018,2Q 2018;,3.96
Gemcabene - INDIGO-1,GEMP,Phase 2b,06/30/2018,2Q 2018;,8.17
Selonsertib (GS-4997),GILD,Phase 2,06/30/2018,2Q 2018;,80.98
Aramchol - ARREST,GLMD,Phase 2b,06/30/2018,2Q 2018;,10.57
GLPG2737 - PELICAN,GLPG,Phase 2,06/30/2018,1H 2018;,112.44
Filgotinib - TORTUGA,GLPG,Phase 2,06/30/2018,2Q 2018;,112.44
Filgotinib - EQUATOR,GLPG,Phase 2,06/30/2018,2Q 2018;,112.44
G1T38 plus Faslodex,GTHX,Phase 1b,06/30/2018,2Q 2018;,26.34
HTX-011,HRTX,Phase 3,06/30/2018,1H 2018;,23.20
IMO-8400,IDRA,Phase 2,06/30/2018,2Q 2018;,2.55
Eftilagimod alpha and Keytruda,IMMP,Phase 1,06/30/2018,1H 2018;,1.85
Epacadostat with Keytruda - ECHO-301,INCY,Phase 3,06/30/2018,1H 2018;,93.16
Ruxolitinib - REACH 1,INCY,Phase 3,06/30/2018,1H 2018;,93.16
IPI-549 + Nivolumab,INFI,Phase 1,06/30/2018,2Q 2018;,2.04
IONIS-HTT Rx,IONS,Phase 1/2,06/30/2018,1H 2018;,50.22
JTX-2011,JNCE,Phase 1/2,06/30/2018,1H 2018;,21.76
Esketamine,JNJ,Phase 3,06/30/2018,2018;,147.36
KP415,KMPH,Phase 3,06/30/2018,2Q 2018;,5.66
Tipifarnib,KURA,Phase 2,06/30/2018,1H 2018;,17.80
MM-141 - CARRIE,MACK,Phase 2,06/30/2018,1H 2018;,10.82
NexoBrid,MDWD,Phase 3,06/30/2018,1H 2018;,4.45
Pracinostat in combination with Vidaza,MEIP,Phase 2,06/30/2018,1H 2018;,2.20
Margetuximab in combination with pembrolizumab,MGNX,Phase 2,06/30/2018,1H 2018;,19.19
MAT2501,MTNB,Phase 2,06/30/2018,2Q 2018;,1.18
NBI-74788,NBIX,Phase 2a,06/30/2018,1H 2018;,80.68
Indoximod + gemcitabine and nab-paclitaxel,NLNK,Phase 2,06/30/2018,1H 2018;,8.62
LEE011: MONALEESA-3,NVS,Phase 3,06/30/2018,2Q 2018;,86.94
Neratinib,PBYI,Phase 3,06/30/2018,1H 2018;,91.60
PF708 and Forteo,PFNX,Phase 3,06/30/2018,1H 2018;,3.20
NEOD001 PRONTO,PRTA,Phase 2b,06/30/2018,2Q 2018;,39.52
PLX-PAD (stem cells),PSTI,Phase 2,06/30/2018,1H 2018;,1.51
Supinoxin,RNN,Phase 2a,06/30/2018,2Q 2018;,2.40
RXDX-105,RXDX,Phase 1b,06/30/2018,1H 2018;,26.95
Samcyprone - RXI-SCP-1502,RXII,Phase 2,06/30/2018,1Q/2Q 2018;,4.42
Setmelanotide,RYTM,Phase 2,06/30/2018,1H 2018;,27.89
SAGE-217,SAGE,Phase 2,06/30/2018,2Q 2018;,169.46
COR-003 (levoketoconazole) - SONICS,SBBP,Phase 3,06/30/2018,2Q 2018;,8.55
SB-525 cDNA gene therapy,SGMO,Phase 1/2,06/30/2018,1H 2018;,17.75
SB-318,SGMO,Phase 1/2,06/30/2018,1H 2018;,17.75
SB-913 - CHAMPIONS,SGMO,Phase 1/2,06/30/2018,1H 2018;,17.75
Entinostat plus Keytruda - ENCORE 601,SNDX,Phase 1/2,06/30/2018,1H 2018;,10.17
E2112,SNDX,Phase 3,06/30/2018,1H 2018;,10.17
SGX301 (synthetic hypericin),SNGX,Phase 3,06/30/2018,1H 2018;,2.13
SPR741,SPRO,Phase 1b,06/30/2018,1H 2018;,12.06
Aironite - INDIE,SVRA,Phase 2,06/30/2018,1H 2018;,13.00
TD-9855,TBPH,Phase 2a,06/30/2018,1H 2018;,28.32
TRC253,TCON,Phase 1/2,06/30/2018,1H 2018;,2.80
TRC105 and Inlyta,TCON,Phase 2,06/30/2018,1H 2018;,2.80
TG-1101 and TGR-1202 - UNITY-CLL study,TGTX,Phase 3,06/30/2018,2Q 2018;,9.35
TNX-102 SL,TNXP,Phase 3,06/30/2018,1H 2018;,3.81
Toca 511 & Toca FC,TOCA,Phase 2/3,06/30/2018,1H 2018;,14.12
TPIV200,TPIV,Phase 2,06/30/2018,1H 2018;,3.96
Niraparib and Keytruda (TOPACIO),TSRO,Phase 1/2,06/30/2018,1H 2018;,63.91
Ropinirole implant,TTNP,Phase 1/2,06/30/2018,1H 2018;,1.28
VCL-HB01 HSV-2 Therapeutic Vaccine,VICL,Phase 2,06/30/2018,2Q 2018;,1.87
VK2809,VKTX,Phase 2,06/30/2018,1H 2018;,4.65
RPL554,VRNA,Phase 2a,06/30/2018,1H 2018;,12.84
ACE-083,XLRN,Phase 2,06/30/2018,1H 2018;,43.04
Dasiglucagon,ZEAL,Phase 3,06/30/2018,2Q 2018;,15.05
ZX008 - Study 1504,ZGNX,Phase 3,06/30/2018,2Q 2018;,35.95
Inotersen (IONIS-TTRRx),IONS,PDUFA priority review,07/06/2018,,50.22
RBP-7000,DRRX,PDUFA,07/28/2018,,1.20
Buprenorphine,INSY,PDUFA,07/28/2018,,8.69
Givosiran,ALNY,Phase 3,07/31/2018,Mid-2018;,124.83
Eculizumab,ALXN,Phase 3,07/31/2018,Mid-2018;,121.05
Oraxol,ATNX,Phase 3,07/31/2018,Mid-2018;,17.33
BL-8040,BLRX,Phase 2,07/31/2018,Mid-2018;,1.09
CX-072,CMTX,Phase 2,07/31/2018,Mid-2018;,10.00
CX 072,CTMX,Phase 1/2,07/31/2018,Mid-2018;,25.55
Vicinium,EBIO,Phase 3,07/31/2018,Mid-2018;,0.82
FMX103,FOMX,Phase 3,07/31/2018,Mid-2018;,6.41
FMX101 - FX2017-22,FOMX,Phase 3,07/31/2018,Mid-2018;,6.41
AEVI-001 (NFC-1),GNMX,Phase 2,07/31/2018,Mid-2018;,1.50
AEVI-002 (Anti-LIGHT mAb),GNMX,Phase 1/2,07/31/2018,Mid-2018;,1.50
Lico-cel (CD-19 JCAR017) - TRANSCEND,JUNO,Phase 1/2,07/31/2018,2018;,67.81
Ramucirumab,LLY,Phase 3,07/31/2018,Mid-2018;,85.49
Sitravatinib plus nivolumab,MRTX,Phase 2,07/31/2018,Mid-2018;,25.60
OBE2109 - EDELWEISS,OBSV,Phase 2b,07/31/2018,Mid-2018;,9.73
Pulmazole (PUR1900),PULM,Phase 1,07/31/2018,Mid-2018;,1.48
RHB-104 MAP US,RDHL,Phase 3,07/31/2018,Mid-2018;,5.24
SCY-078 - oral,SCYX,Phase 2b,07/31/2018,Mid-2018;,1.85
SNS-062,SNSS,Phase 1/2,07/31/2018,Mid-2018;,4.24
SPR994,SPRO,Phase 1,07/31/2018,Mid-2018;,12.06
SRP-5051,SRPT,Phase 1/2,07/31/2018,Mid-2018;,62.38
RPL554,VRNA,Phase 2b,07/31/2018,Mid-2018;,12.84
AV-101,VTGN,Phase 2,07/31/2018,Mid-2018.;,1.21
Luspatercept - BELIEVE,XLRN,Phase 3,07/31/2018,Mid-2018;,43.04
Luspatercept - MEDALIST,XLRN,Phase 3,07/31/2018,Mid-2018;,43.04
ZGN-1061,ZFGN,Phase 2,07/31/2018,Mid-2018;,6.05
EYLEA,REGN,PDUFA,08/11/2018,,371.53
IDP-121,VRX,PDUFA,08/26/2018,,21.52
Volanesorsen - APPROACH,AKCA,PDUFA,08/30/2018,,17.90
AEB1102,AGLE,Phase 1/2,09/30/2018,3Q 2018;,6.75
rAAV-hRS1,AGTC,Phase 1/2,09/30/2018,3Q 2018 est.;,4.10
Vascepa REDUCE-IT outcomes trial,AMRN,–,09/30/2018,3Q 2018;,3.97
AQX-1125 LEADERSHIP,AQXP,Phase 3,09/30/2018,3Q 2018;,11.75
AVP-786,CNCE,Phase 3,09/30/2018,3Q 2018;,19.61
Exendin 9-39,EIGR,Phase 2,09/30/2018,3Q 2018;,8.85
FLX-787 - COMMEND US trial,FLKS,Phase 2,09/30/2018,3Q 2018;,3.85
F/TAF (Descovy),GILD,Phase 3,09/30/2018,3Q 2018;,80.98
NeoCart,HSGX,Phase 3,09/30/2018,3Q 2018;,2.56
Concizumab - explorer,NVO,Phase 2,09/30/2018,3Q 2018;,57.79
Somapacitan (NN8640) - REAL 3,NVO,Phase 3,09/30/2018,3Q 2018;,57.79
1404,PGNX,Phase 3,09/30/2018,3Q 2018;,6.27
RG-012 - HERA,RGLS,Phase 2,09/30/2018,3Q 2018;,1.40
MitoGel - OLYMPUS,URGN,Phase 3,09/30/2018,3Q 2018;,43.00
VTI-308,VTL,Phase 3,09/30/2018,3Q 2018;,5.50
"Galcanezumab - EVOLVE-1, EVOLVE-2 and REGAIN",LLY,PDUFA,10/10/2018,,85.49
Sarecycline,PRTK,PDUFA,10/19/2018,4Q 2018;,15.93
Doravirine (MK-1439),MRK,PDUFA,10/23/2018,,61.28
Oliceridine (TRV130),TRVN,PDUFA,11/02/2018,,1.75
Adalimumab,NVS,PDUFA,11/16/2018,"Nov 16, 2018 est only;",86.94
ABT-494 - SELECT-COMPARE,ABBV,Phase 3,12/31/2018,2018;,104.64
Imbruvica - PHOENIX,ABBV,Phase 3,12/31/2018,2018;,104.64
"ARB-1467, tenofovir, and pegylated interferon",ABUS,Phase 2,12/31/2018,2H 2018;,5.20
ACI-24 (anti-Abeta vaccine),ACIU,Phase 1/2,12/31/2018,2018;,13.14
ATI-50002 - dose ranging,ACRS,Phase 2,12/31/2018,YE 2018;,24.40
ADVM-043,ADVM,Phase 1/2,12/31/2018,2H 2018;,4.90
Brazikumab,AGN,Phase 2b,12/31/2018,2018;,181.33
ABICIPAR,AGN,Phase 3,12/31/2018,2H 2018;,181.33
AR101 RAMSES,AIMT,Phase 3,12/31/2018,2H 2018;,38.90
Vadadustat - TRILO2GY,AKBA,Phase 3,12/31/2018,YE 2018;,14.71
Vadadustat - FO2RWARD,AKBA,Phase 2,12/31/2018,YE 2018;,14.71
AKCEA-ANGPTL3-LRx,AKCA,Phase 2,12/31/2018,2018;,17.90
AKCEA-APO(a)-LRx,AKCA,Phase 2b,12/31/2018,2018;,17.90
ADX-102,ALDX,Phase 2b,12/31/2018,2H 2018;,6.90
ADX-102,ALDX,Phase 3,12/31/2018,2H 2018;,6.90
ADX-102,ALDX,Phase 2,12/31/2018,2H 2018;,6.90
ALLN-177,ALNA,Phase 2,12/31/2018,2H 2018;,9.65
ALN-CC5 (cemdisiran),ALNY,Phase 1/2,12/31/2018,2018;,124.83
ALXN1210,ALXN,Phase 1/2,12/31/2018,2Q 2018;,121.05
APL-2 subcutaneous,APLS,Phase 2,12/31/2018,2H 2018;,18.90
ARGX-113,ARGX,Phase 2,12/31/2018,2H 2018;,66.33
ARGX-113,ARGX,Phase 2,12/31/2018,2H 2018;,66.33
AST-VAC2,AST,Phase 1/2,12/31/2018,2H 2018;,2.40
Endoxifen,ATOS,Phase 2,12/31/2018,2018;,0.33
Endoxifen,ATOS,Phase 2,12/31/2018,2018;,0.33
Voclosporin,AUPH,Phase 2,12/31/2018,2H 2018;,5.57
Voclosporin,AUPH,Phase 2,12/31/2018,2H 2018;,5.57
Farxiga - DECLARE,AZN,Phase 3,12/31/2018,2H 2018;,35.44
Benralizumab - TERRANOVA,AZN,Phase 3,12/31/2018,2H 2018;,35.44
Durvalumab +/- tremelimumab (NEPTUNE),AZN,Phase 3,12/31/2018,2H 2018;,35.44
Anifrolumab,AZN,Phase 3,12/31/2018,2H 2018;,35.44
Raxatrigine - BIIB074 (Nav1.7 inhibitor),BIIB,Phase 2,12/31/2018,2018;,342.41
BAN2401 (Aβ mAb),BIIB,Phase 2,12/31/2018,2H 2018;,342.41
BIVV001 (EXTEN-A),BIVV,Phase 1/2,12/31/2018,2018;,64.11
INOpulse delivery device,BLPH,Phase 2b,12/31/2018,YE 2018;,2.24
INOpulse delivery device,BLPH,Phase 2,12/31/2018,YE 2018;,2.24
INOpulse delivery device,BLPH,Phase 3,12/31/2018,2018;,2.24
BL-8040 in combination with KEYTRUDA - COMBAT trial,BLRX,Phase 2,12/31/2018,,1.09
BL-8040,BLRX,Phase 2b,12/31/2018,2018;,1.09
CM-602 – Opdivo + Elo + SOC,BMY,Phase 3,12/31/2018,2H 2018;,62.28
CM-459 – Opdivo,BMY,Phase 3,12/31/2018,2H 2018;,62.28
CM-451 – Opdivo + Yervoy,BMY,Phase 3,12/31/2018,2H 2018;,62.28
Plinabulin,BYSI,Phase 3,12/31/2018,2018;,25.97
Namodenoson (CF102),CANF,Phase 2,12/31/2018,2H 2018;,1.74
Tucatinib - MOUNTAINEER,CASC,Phase 2,12/31/2018,2018;,4.27
OTEZLA - SPSO-001,CELG,Phase 3,12/31/2018,2018;,102.65
REVLIMID - ROBUST,CELG,Phase 3,12/31/2018,2018;,102.65
MM-007 OPTIMISMM,CELG,Phase 3,12/31/2018,2018;,102.65
Oral Azacitidine - CC-486-AML-001,CELG,Phase 3,12/31/2018,2018;,102.65
ABRAXANE - PANC-003 apact,CELG,Phase 3,12/31/2018,YE 2018;,102.65
ABRAXANE - IMpower 130 ( I/O Combo),CELG,Phase 3,12/31/2018,2018;,102.65
ABRAXANE - IMpower 131 ( I/O Combo),CELG,Phase 3,12/31/2018,2018;,102.65
ABRAXANE - IMPassion ( I/O Combo),CELG,Phase 3,12/31/2018,2018;,102.65
CF-301,CFRX,Phase 2,12/31/2018,4Q 2018;,1.12
IV Brincidofovir,CMRX,Phase 2,12/31/2018,2H 2018;,4.93
CX-2009 - PROCLAIM,CMTX,Phase 2,12/31/2018,2H 2018;,10.00
Emricasan,CNAT,Phase 2,12/31/2018,2H 2018;,4.71
CTP-543,CNCE,Phase 2a,12/31/2018,2H 2018;,19.61
CX 2009,CTMX,Phase 1/2,12/31/2018,2H 2018;,25.55
DCC-3014,DCPH,Phase 1,12/31/2018,2H 2018;,27.47
Fulvestrant,EGRX,Phase 3,12/31/2018,4Q 2018;,58.84
Ubenimex - ULTRA,EIGR,Phase 2,12/31/2018,2H 2018;,8.85
Tazemetostat,EPZM,Phase 2,12/31/2018,2018;,15.25
Bempedoic Acid/ Ezetimibe (1002FDC-053),ESPR,Phase 3,12/31/2018,4Q 2018;,77.20
Amphora - AMPOWER,EVFM,Phase 3,12/31/2018,4Q 2018;,11.68
Roxadustat - ANDES,FGEN,Phase 3,12/31/2018,2018;,47.85
FLX-787,FLKS,Phase 2,12/31/2018,2018;,3.85
Zilretta - SHIP,FLXN,Phase 2,12/31/2018,2H 2018;,23.41
Gemcabene - AZURE-1,GEMP,Phase 2,12/31/2018,2H 2018;,8.17
Tirabrutinib (GS-4059),GILD,Phase 2,12/31/2018,2H 2018;,80.98
GS-9876,GILD,Phase 2,12/31/2018,2H 2018;,80.98
GS-5734,GILD,Phase 2,12/31/2018,2H 2018;,80.98
Axicabtagene ciloleucel - KTE-C19 (ZUMA-2),GILD,Phase 2,12/31/2018,2018;,80.98
Axicabtagene ciloleucel - KTE-C19 (ZUMA-3),GILD,Phase 1/2,12/31/2018,2018;,80.98
Axicabtagene ciloleucel - KTE-C19 (ZUMA-4),GILD,Phase 1/2,12/31/2018,2018;,80.98
Trilaciclib,GTHX,Phase 2,12/31/2018,4Q 2018;,26.34
Enobosarm,GTXI,Phase 2,12/31/2018,YE 2018;,13.25
Epidiolex,GWPH,Phase 3,12/31/2018,2H 2018;,132.42
Epidiolex,GWPH,Phase 3,12/31/2018,2H 2018;,132.42
PEGPH20 - HALO-301,HALO,Phase 3,12/31/2018,Late 4Q 2018;,17.98
PEGPH20 in combination with KEYTRUDA,HALO,Phase 1b,12/31/2018,2018;,17.98
HS-110 and nivolumab (Opdivo),HTBX,Phase 1b,12/31/2018,2H 2018;,0.34
Kadcyla (KATHERINE).,IMGN,Phase 3,12/31/2018,2018;,8.03
IMM-124E,IMRN,Phase 2,12/31/2018,4Q 2018;,7.11
IMM-529,IMRN,Phase 1/2,12/31/2018,4Q 2018;,7.11
Cannabidiol,INSY,Phase 2,12/31/2018,YE 2018;,8.69
LN-145,IOVA,Phase 2,12/31/2018,2018;,10.70
STELARA (USTEKINUMAB),JNJ,Phase 3,12/31/2018,2018;,147.36
JCARH125,JUNO,Phase 1,12/31/2018,2018;,67.81
Selinexor - SADAL,KPTI,Phase 2b,12/31/2018,2H 2018;,10.01
Flortaucipir F 18 (Tau imaging agent),LLY,Phase 3,12/31/2018,2018;,85.49
MM-121 (SHERBOC),MACK,Phase 2,12/31/2018,2H 2018;,10.82
MM-121,MACK,Phase 2,12/31/2018,2H 2018;,10.82
Annamycin,MBRX,Phase 1/2,12/31/2018,2018;,1.85
Ganaxolone,MRNS,Phase 2,12/31/2018,2018;,6.83
INGREZZA - T-Force GOLD,NBIX,Phase 2b,12/31/2018,Late-2018;,80.68
NUC-3373,NCNA,Phase 1,12/31/2018,2018;,20.51
NUC-1031 (Acelarin),NCNA,Phase 2,12/31/2018,2018;,20.51
NSR-RPGR,NITE,Phase 1/2,12/31/2018,2018;,14.73
RSV vaccine - prepare trial,NVAX,Phase 3,12/31/2018,4Q 2018 or 1Q 2019;,1.97
Tumor Treating Fields (TTFields) STELLAR,NVCR,Phase 2,12/31/2018,2018;,21.10
QVM149,NVS,Phase 3,12/31/2018,2018;,86.94
OBE022 - PROLONG,OBSV,Phase 2a,12/31/2018,YE 2018;,9.73
OTX-TP,OCUL,Phase 3,12/31/2018,2H 2018;,6.23
ImmunoPulse IL-12 - PISCES,ONCS,Phase 2b,12/31/2018,2018;,2.04
IV Rigosertib - INSPIRE,ONTX,Phase 3,12/31/2018,2H 2018;,1.77
OV101 (STARS),OVID,Phase 2,12/31/2018,2H 2018;,9.18
PRS-080,PIRS,Phase 2a,12/31/2018,2H 2018;,7.42
QR-010,PRQR,Phase 1/2,12/31/2018,2018;,3.00
PUR1800,PULM,Phase 2a,12/31/2018,4Q 2018;,1.48
AMT-061,QURE,Phase 3,12/31/2018,YE 2018;,17.99
DTX301,RARE,Phase 1/2,12/31/2018,2H 2018;,49.16
RHB-105 - ERADICATE Hp 2,RDHL,Phase 3,12/31/2018,2H 2018;,5.24
Dupixent (dupilumab),REGN,Phase 3,12/31/2018,2018;,371.53
Bardoxolone methyl - CATALYST,RETA,Phase 3,12/31/2018,2H 2018;,29.79
RGX-501,RGNX,Phase 1/2,12/31/2018,Late 2018;,27.10
Fostamatinib,RIGL,Phase 2,12/31/2018,2018;,4.23
"RT002 - SAKURA 1, 2 and 3",RVNC,Phase 3,12/31/2018,2H 2018;,33.95
COR-003 (levoketoconazole) - LOGICS,SBBP,Phase 3,12/31/2018,4Q 2018;,8.55
SCY-078 - oral - CARES,SCYX,Phase 3,12/31/2018,4Q 2018;,1.85
SCY-078 - oral (FURI),SCYX,Phase 3,12/31/2018,4Q 2018;,1.85
ADCETRIS in combination with chemotherapy - ECHELON-2,SGEN,Phase 3,12/31/2018,2018;,53.48
SB-FIX,SGMO,Phase 1/2,12/31/2018,2018;,17.75
SNA-001,SNNA,Phase 3,12/31/2018,2H 2018;,18.98
SNA-001,SNNA,Phase 3,12/31/2018,2H 2018;,18.98
Isatuximab,SNY,Phase 3,12/31/2018,4Q 2018;,44.60
Microdystrophin gene therapy rAAVrh74.MCK.GALGT2,SRPT,Phase 1/2,12/31/2018,2H 2018;,62.38
GALGT2 gene therapy,SRPT,Phase 1/2,12/31/2018,2H 2018;,62.38
Molgradex - IMPALA,SVRA,Phase 3,12/31/2018,YE 2018;,13.00
Closed Triple - CAPTAIN,TBPH,Phase 3,12/31/2018,2H 2018;,28.32
TRC105,TCON,Phase 2,12/31/2018,2018;,2.80
TRC102,TCON,Phase 2,12/31/2018,2018;,2.80
TRC105 (TAPPAS),TCON,Phase 3,12/31/2018,2H 2018;,2.80
Niraparib - AVANOVA,TSRO,Phase 1/2,12/31/2018,2H 2018;,63.91
Esuberaprost - BEAT,UTHR,Phase 3,12/31/2018,2018;,139.51
Orenitram,UTHR,Phase 3,12/31/2018,2H 2018;,139.51
Tradipitant,VNDA,Phase 2,12/31/2018,YE 2018;,14.50
HETLIOZ (tasimelteon),VNDA,Phase 3,12/31/2018,2018;,14.50
XBIO-101,XBIT,Phase 2,12/31/2018,YE 2018;,4.68
XmAb5871,XNCR,Phase 2,12/31/2018,4Q 2018;,21.56
Dasiglucagon,ZEAL,Phase 3,12/31/2018,2H 2018;,15.05
AR101 ARTEMIS,AIMT,Phase 3,03/31/2019,Early 2019;,38.90
TransCon,ASND,Phase 3,03/31/2019,1Q 2019;,51.53
CLBS03,CLBS,Phase 2,03/31/2019,Early 2019;,4.11
Suprachoroidal CLS-TA - SAPPHIRE,CLSD,Phase 3,03/31/2019,1Q 2019;,6.44
ThermoDox - OPTIMA,CLSN,Phase 3,03/31/2019,1Q 2019;,2.67
Mino-Lok,CTXR,Phase 3,03/31/2019,Early 2019;,4.34
Danirixin,GSK,Phase 2b,03/31/2019,1Q 2019;,38.20
ORMD-0801,ORMP,Phase 2b,03/31/2019,Early 2019;,8.38
Vonapanitase (PRT-201) PATENCY-2,PRTO,Phase 3,03/31/2019,1Q 2019;,2.45
RX-3117 in combination with Abraxane,RNN,Phase 2a,03/31/2019,1Q 2019;,2.40
ATA188,ATRA,Phase 1,06/30/2019,1H 2019;,29.50
ATA 129 - ALLELE,ATRA,Phase 3,06/30/2019,1H 2019;,29.50
CM-568 - Opdivo + Yervoy,BMY,Phase 2,06/30/2019,2H 2018 – 1H 2019;,62.28
Oral Brincidofovir,CMRX,–,06/30/2019,1H 2019;,4.93
Emricasan,CNAT,Phase 2,06/30/2019,1H 2019;,4.71
CEVA101,FBIO,Phase 2,06/30/2019,1H 2019;,3.96
GBT440 - HOPE,GBT,Phase 3,06/30/2019,1H 2019;,53.95
Tapinarof (GSK2894512),GSK,Phase 3,06/30/2019,1H 2019;,38.20
Inhaled PI3Kδ inhibitor,GSK,Phase 2b,06/30/2019,1H 2019;,38.20
Ocaliva (Obeticholic acid (OCA)) - REGENERATE,ICPT,Phase 3,06/30/2019,1H 2019;,57.72
Alpha-1 antitrypsin (AAT),KMDA,Phase 1/2,06/30/2019,1H 2019;,5.60
MIN-101,NERV,Phase 3,06/30/2019,1H 2019;,6.80
RA101495,RARX,Phase 2,06/30/2019,1H 2019;,8.00
Setmelanotide,RYTM,Phase 3,06/30/2019,1H 2019;,27.89
Entinostat plus Tecentriq - ENCORE 603,SNDX,Phase 1/2,06/30/2019,1H 2019;,10.17
SNA-120,SNNA,Phase 2b,06/30/2019,1H 2019;,18.98
Telavancin,TBPH,Phase 3,06/30/2019,2018/19;,28.32
TG-1101 and TGR-1202 - UNITY-NHL study,TGTX,Phase 2/3,06/30/2019,1H 2019;,9.35
AV-101,VTGN,Phase 2,06/30/2019,1H 2019;,1.21
Fitusiran (ATLAS),ALNY,Phase 3,10/31/2019,Mid-late 2019;,124.83
Venetoclax,ABBV,Phase 3,12/31/2019,2019;,104.64
Axalimogene filolisbac + durvalumab,ADXS,Phase 1/2,12/31/2019,2019;,2.93
AFM13,AFMD,Phase 2,12/31/2019,2019;,1.30
RAPASTINEL,AGN,Phase 3,12/31/2019,2019;,181.33
Vadadustat - INNO2VATE,AKBA,Phase 3,12/31/2019,2019;,14.71
Vadadustat - PRO2TECT,AKBA,Phase 3,12/31/2019,2019;,14.71
AKCEA-ANGPTL3-LRx,AKCA,Phase 2,12/31/2019,2019;,17.90
AKCEA-APOCIII-LRx,AKCA,Phase 2b,12/31/2019,2019;,17.90
ALLN-177,ALNA,Phase 3,12/31/2019,2H 2019;,9.65
KYPROLIS (ARROW),AMGN,Phase 3,12/31/2019,2019;,189.28
ANB020,ANAB,Phase 2b,12/31/2019,2019;,114.91
Iomab-B,ATNM,Phase 3,12/31/2019,2H 2019;,0.74
AZD3293,AZN,Phase 3,12/31/2019,2019;,35.44
Durvalumab +/- tremelimumab (DANUBE),AZN,Phase 3,12/31/2019,2019;,35.44
Brilinta (THEMIS),AZN,Phase 3,12/31/2019,2019;,35.44
NurOwn,BCLI,Phase 3,12/31/2019,Late 2019;,3.56
Vosoritide,BMRN,Phase 3,12/31/2019,2H 2019;,89.12
CM-649 – Opdivo+ Yervoy or Chemo,BMY,Phase 3,12/31/2019,2019;,62.28
CM-9LA Opdivo + Yervoy + Chemo,BMY,Phase 3,12/31/2019,2019;,62.28
CM-651 – Opdivo + Yervoy,BMY,Phase 3,12/31/2019,2019;,62.28
REVLIMID - MAGNIFY NHL-010,CELG,Phase 3,12/31/2019,2019;,102.65
Mycapssa - OPTIMAL,CHMA,Phase 3,12/31/2019,2019;,1.65
Emricasan,CNAT,Phase 2b,12/31/2019,2019;,4.71
DCC-2618 - INVICTUS,DCPH,Phase 3,12/31/2019,2019;,27.47
NeuVax in combination with Herceptin,GALE,Phase 2,12/31/2019,4Q 2019;,0.26
Mepolizumab - SYNAPSE,GSK,Phase 3,12/31/2019,2019;,38.20
Kadcyla (KAITLIN),IMGN,Phase 3,12/31/2019,2019;,8.03
Eftilagimod Alpha  - Active Immunotherapy PAClitaxel (AIPAC),IMMP,Phase 2b,12/31/2019,2019;,1.85
IMM-124E,IMRN,Phase 2,12/31/2019,2019;,7.11
Ruxolitinib - REACH 3,INCY,Phase 3,12/31/2019,2019;,93.16
INVOKANA - CREDENCE,JNJ,Phase 3,12/31/2019,2019;,147.36
DARZALEX (Daratumumab),JNJ,Phase 3,12/31/2019,2019;,147.36
KVD001,KALV,Phase 2,12/31/2019,2H 2019;,11.23
Selinexor - SEAL,KPTI,Phase 2/3,12/31/2019,2019;,10.01
Selinexor - BOSTON,KPTI,Phase 3,12/31/2019,2019;,10.01
Inclisiran,MDCO,Phase 3,12/31/2019,YE 2019;,24.83
MK-8931 (019) - Verubecestat,MRK,Phase 3,12/31/2019,2019;,61.28
QAW039 (fevipiprant),NVS,Phase 3,12/31/2019,2019;,86.94
OMB157 (ofatumumab),NVS,Phase 3,12/31/2019,2019;,86.94
Entresto - PARAGON,NVS,Phase 3,12/31/2019,2019;,86.94
Entresto - PARADISE,NVS,Phase 3,12/31/2019,2019;,86.94
AIN457 (Cosentyx),NVS,Phase 3,12/31/2019,2019;,86.94
OBE2109 - PRIMROSE 2,OBSV,Phase 3,12/31/2019,2H 2019;,9.73
OBE2109 - PRIMROSE,OBSV,Phase 3,12/31/2019,2H 2019;,9.73
Zimura,OPHT,Phase 2a,12/31/2019,2H 2019;,2.94
OvaPrime,OVAS,Phase 1/2,12/31/2019,2019;,1.09
Bardoxolone methyl - CARDINAL,RETA,Phase 3,12/31/2019,2H 2019;,29.79
Omaveloxolone - MOXIe,RETA,Phase 2,12/31/2019,2H 2019;,29.79
Sci-B-Vac - PROTECT,VBIV,Phase 3,12/31/2019,2H 2019;,4.19
ZYN002,ZYNE,Phase 2/3,12/31/2019,2019;,11.45
Axalimogene filolisbac - AIM2CERV Trial,ADXS,Phase 3,06/30/2020,2020/21;,2.93
Terlipressin,MNK,Phase 3,06/30/2020,1H 2020;,21.30
H.P. Acthar Gel,MNK,Phase 2,06/30/2020,1H 2020;,21.30
UVADEX (methoxsalen) and Therakos,MNK,Phase 3,06/30/2020,1H 2020;,21.30
RELAMORELIN,AGN,Phase 3,12/31/2020,2020;,181.33
Durvalumab (ADJUVANT),AZN,Phase 3,12/31/2020,2020;,35.44
BL-8040 GENESIS,BLRX,Phase 3,12/31/2020,2020;,1.09
Edasalonexent (CAT-1004),CATB,Phase 3,12/31/2020,2020;,1.53
REVLIMID - MAGNIFY NHL-008,CELG,Phase 3,12/31/2020,2020;,102.65
Mycapssa - MPOWERED,CHMA,Phase 3,12/31/2020,2020;,1.65
Anabasum (Resunab),CRBP,Phase 3,12/31/2020,2020;,8.25
Daprodustat - ASCEND-D,GSK,Phase 3,12/31/2020,2020;,38.20
Ruxolitinib - REACH 2,INCY,Phase 3,12/31/2020,2020;,93.16
GDC-0084,KZIA,Phase 2,12/31/2020,2020;,3.38
Tumor Treating Fields (TTFields) METIS,NVCR,Phase 3,12/31/2020,2020;,21.10
Tesetaxel - CONTESSA,ODT,Phase 3,12/31/2020,2020;,22.30
Zimura,OPHT,Phase 2b,12/31/2020,2020;,2.94
NEOD001 VITAL,PRTA,Phase 3,12/31/2020,2020;,39.52
Tumor Treating Fields (TTFields) LUNAR,NVCR,Phase 3,12/31/2021,2021;,21.10
CNP 520,NVS,Phase 2/3,12/31/2023,2023;,86.94
